8-K: AbbVie Reports Strong Q3 2024 Results, Raises Full-Year Guidance and Dividend

AbbVie announced its third-quarter 2024 financial results, showcasing revenue growth and increased adjusted earnings per share, while also raising its full-year guidance and dividend.

Summary

• AbbVie reported a third-quarter diluted EPS of $0.88 on a GAAP basis, a decrease of 12.0 percent, and an adjusted diluted EPS of $3.00, an increase of 1.7 percent.
• The results include an unfavorable impact of $0.04 per share related to acquired IPR&D and milestones expense.
• Net revenues for the third quarter were $14.460 billion, a 3.8 percent increase on a reported basis and a 4.9 percent increase on an operational basis.
• The immunology portfolio generated $7.046 billion in global net revenues, a 3.9 percent increase on a reported basis and a 4.8 percent increase on an operational basis.
• Humira global net revenues were $2.227 billion, a decrease of 37.2 percent on a reported basis.
• Skyrizi global net revenues were $3.205 billion, a 50.8 percent increase on a reported basis.
• Rinvoq global net revenues were $1.614 billion, a 45.3 percent increase on a reported basis.
• The oncology portfolio saw global net revenues of $1.687 billion, an 11.6 percent increase on a reported basis and a 13.0 percent increase on an operational basis.
• The neuroscience portfolio generated $2.363 billion in global net revenues, a 15.6 percent increase on a reported basis and a 16.0 percent increase on an operational basis.
• The aesthetics portfolio had global net revenues of $1.239 billion, a decrease of 0.1 percent on a reported basis, but an increase of 1.8 percent on an operational basis.
• AbbVie raised its 2024 adjusted diluted EPS guidance range from $10.67 $10.87 to $10.90 $10.94, which includes an unfavorable impact of $0.64 per share related to acquired IPR&D and milestones expense incurred year-to-date.
• The company announced a 5.8 percent dividend increase for 2025, with the new dividend of $1.64 per share payable in February 2025.

Sentiment

Score: 8

Explanation: The sentiment is positive due to strong revenue growth in key areas, successful acquisitions, and an increased dividend. However, the decline in Humira revenue and some weakness in the aesthetics portfolio temper the overall outlook.

Positives

• AbbVie's adjusted diluted EPS increased by 1.7 percent year-over-year, reaching $3.00.
• Net revenues grew by 3.8 percent on a reported basis, reaching $14.460 billion.
• Skyrizi and Rinvoq showed strong growth, with revenue increases of 50.8 percent and 45.3 percent respectively.
• The neuroscience portfolio experienced a significant 15.6 percent increase in net revenues.
• The company successfully acquired Cerevel and Aliada, enhancing its pipeline and technology.
• AbbVie raised its full-year adjusted diluted EPS guidance, indicating confidence in future performance.
• The dividend was increased by 5.8 percent, demonstrating a commitment to returning value to shareholders.
• Skyrizi received European Commission approval for ulcerative colitis, expanding its market reach.
• The company's oncology portfolio saw an 11.6 percent increase in revenue.

Negatives

• GAAP diluted EPS decreased by 12.0 percent to $0.88.
• Humira net revenues decreased by 37.2 percent on a reported basis, reflecting the impact of biosimilar competition.
• The aesthetics portfolio saw a slight decrease of 0.1 percent in net revenues on a reported basis.
• Juvederm net revenues decreased by 19.7 percent on a reported basis.
• The results include an unfavorable impact of $0.04 per share related to acquired IPR&D and milestones expense.
• The company's GAAP operating margin was 26.5 percent, lower than the adjusted operating margin of 46.7 percent.

Risks

• The decline in Humira revenue due to biosimilar competition poses a significant risk to overall revenue.
• Acquired IPR&D and milestones expenses continue to negatively impact earnings per share.
• The aesthetics portfolio is experiencing some headwinds, with a slight decrease in reported revenue.
• The company faces risks related to intellectual property, competition, and regulatory changes.
• The company's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.

Future Outlook

AbbVie raised its full-year 2024 adjusted diluted EPS guidance to $10.90 $10.94. The company expects to close the acquisition of Aliada Therapeutics in the fourth quarter of 2024. Topline results from the TEMPO-2 trial for tavapadon are expected by the end of 2024.

Management Comments

• Robert A. Michael, chief executive officer, stated, 'We delivered another quarter of strong commercial execution and significant pipeline progress.'
• He also mentioned, 'Based upon the momentum of AbbVie's business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend.'

Industry Context

The results reflect the ongoing shift in the pharmaceutical industry, with companies like AbbVie navigating the impact of biosimilar competition on established products like Humira while focusing on growth through new product launches and strategic acquisitions. The company's focus on immunology, oncology, neuroscience, and aesthetics aligns with key growth areas in the healthcare sector.

Comparison to Industry Standards

• AbbVie's performance in the immunology space, particularly with Skyrizi and Rinvoq, is strong compared to competitors like Johnson & Johnson and Novartis, who also have significant immunology portfolios.
• The decline in Humira revenue is consistent with industry trends as biosimilars erode market share of established biologics, similar to what has been seen with other blockbuster drugs.
• The growth in AbbVie's neuroscience portfolio, especially with Vraylar and Botox Therapeutic, positions them well against companies like Eli Lilly and Biogen, who are also investing heavily in this area.
• The acquisition of Cerevel is similar to other large pharmaceutical companies acquiring smaller biotech firms to bolster their pipelines, such as Pfizer's acquisition of Seagen.
• The dividend increase of 5.8 percent is in line with other large pharmaceutical companies that prioritize returning value to shareholders, such as Merck and Bristol Myers Squibb.

Stakeholder Impact

• Shareholders will benefit from the increased dividend and the potential for long-term growth.
• Employees may see opportunities for growth and development due to the company's expansion.
• Customers will have access to new and innovative treatments.
• Suppliers may see increased business opportunities.
• Creditors will be reassured by the company's strong financial performance.

Next Steps

• AbbVie will continue to focus on the commercialization of Skyrizi and Rinvoq.
• The company will integrate Cerevel and Aliada into its operations.
• AbbVie will submit full results from the TEMPO-1 study for tavapadon at future medical meetings and use them to support regulatory submissions.
• The company will continue to develop Botox Cosmetic treatment for MMP in additional global markets.
• AbbVie will continue to advance its pipeline of innovative medicines.

Key Dates

Keywords

AbbVie, Financial Results, Third Quarter, EPS, Revenue, Immunology, Oncology, Neuroscience, Aesthetics, Humira, Skyrizi, Rinvoq, Acquisition, Dividend, Guidance